Neurotech International clinical update on NTI164 treatment for PANDAS/PANS patients

Neurotech International Limited (ASX: $NTI) has announced a significant clinical update on the open-label Phase I/II clinical trial of NTI164 in children diagnosed with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). The trial has shown continued improvements in patients' clinical symptoms to 52 weeks of daily oral treatment with NT1164, with a 38% improvement in the severity of their illness and a 45% improvement in anxiety and depression as measured by the Revised Child Anxiety and Depression Scale - Parent Version (RCADS-P). Neurotech estimates the annual market for PANDAS/PANS to be worth US$1.2 billion.

Executive commentary on NTI164 treatment for PANDAS/PANS patients

Dr Thomas Duthy, Executive Director of Neurotech, expressed, 'The durable response we are seeing in our PANDAS/PANS patients is remarkable in the context of their baseline clinical symptoms immediately prior to commencing NT1164 therapy. When overlaid with the safety benefits, we believe NT1164 provides a therapeutic intervention well-suited in this patient population, where persistent or progressive neuroinflammation is consistently observed.'

Summary of Neurotech International's clinical update on NTI164 treatment for PANDAS/PANS patients

Neurotech International (ASX: $NTI) has reported continued clinical improvement in PANDAS/PANS patients to 52 weeks of NTI164 treatment, with significant improvements in the severity of their illness and anxiety and depression. The Company estimates the annual market for PANDAS/PANS to be worth US$1.2 billion. The extension of the trial for an additional 52 weeks demonstrates the potential of NT1164 as a therapeutic intervention for children with persistent or progressive neuroinflammation. Neurotech's focus on paediatric neurological disorders and the positive outcomes of the trial position the Company as a key player in addressing unmet medical needs in this space.